MedPath

Tagged News

AI Tools Show Promise in Improving HER2 Breast Cancer Classification and Treatment Eligibility

AIPrecision MedicineOncology
  • A multinational study demonstrates that AI assistance significantly improves pathologists' accuracy in HER2 breast cancer scoring, with accuracy rates increasing from 89.1% to 96.1% when AI tools were utilized.
  • The Digital PATH Project, involving 31 partners including pharmaceutical companies and academic centers, validated AI diagnostic technologies using 1,100 breast cancer tissue samples to assess consistency in HER2 expression identification.
  • AI tools particularly enhanced detection of HER2-low and HER2-ultralow expression levels, reducing misclassification by 24.4% and potentially expanding treatment eligibility for antibody-drug conjugates to patients previously classified as HER2-negative.

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425Active, Not RecruitingPhase 3
AstraZeneca
Posted 7/24/2020

VantAI and Blueprint Medicines Expand Collaboration to Tackle "Undruggable" Targets with AI-Powered Proximity Therapeutics

AIDrug Discovery
  • VantAI and Blueprint Medicines have expanded their strategic collaboration for the second time since 2022, incorporating additional drug programs focused on targets previously considered undruggable.
  • The expanded agreement makes VantAI eligible for up to $1.67 billion in milestone payments plus royalties, highlighting significant industry validation for their AI-driven approach to induced proximity therapeutics.
  • The collaboration will leverage VantAI's recently announced Neo-1 foundation model, the first AI system capable of generating molecular glues and other protein-protein interaction modifiers to address complex therapeutic challenges.

A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT06800313RecruitingPhase 1
Halda Therapeutics OpCo, Inc.
Posted 2/24/2025

Poolbeg Pharma Secures £4.1 Million Fundraising to Advance Clinical Programs in Oncology and Obesity

OncologyAICAR-T
  • Poolbeg Pharma has announced a £4.1 million conditional fundraising to advance its POLB 001 Phase 2a trial for cancer immunotherapy-induced Cytokine Release Syndrome and oral GLP-1 proof of concept trial for obesity.
  • The fundraising comprises a £2.655 million placing, £1.345 million in direct subscriptions, and up to £100,000 from a retail offer, with shares issued at 2.5 pence each, representing a 12% discount to the previous closing price.
  • The proceeds will extend Poolbeg's cash runway into 2027, supporting multiple near-term clinical data catalysts including first patient dosing for POLB 001 in H2 2025 and topline data expected in H2 2026.

USC Spine Center Joins Pivotal CLARITY Trial to Evaluate Nociscan for Chronic Low Back Pain

AI
  • Keck Medical Center of USC has joined the CLARITY trial to evaluate Aclarion's Nociscan technology, which uses MR Spectroscopy and AI to identify sources of chronic low back pain.
  • The randomized, multi-center CLARITY trial will enroll 300 patients across prestigious institutions including Johns Hopkins Medicine, Northwestern Medicine, and Texas Back Institute.
  • Nociscan is the first evidence-supported platform to noninvasively distinguish between painful and nonpainful discs in the lumbar spine, potentially transforming diagnosis and treatment for 266 million people worldwide with degenerative spine disease.

Imec Unveils Revolutionary Miniaturized Ingestible Sensor for Non-Invasive Gut Health Monitoring

AI
  • Imec has developed a highly miniaturized ingestible sensor measuring just 2.1cm in length and 0.75cm in diameter, three times smaller than existing capsule endoscopies, capable of monitoring gut health for up to a week.
  • The innovative device is the first to measure redox balance, a marker for oxidative stress and inflammation, alongside pH and temperature throughout the entire gastrointestinal tract without requiring unpleasant bowel preparation.
  • Following successful testing in healthy volunteers, Imec plans to evaluate the sensor in patient populations with cancer and inflammatory disorders in collaboration with Radboud University Medical Center.

Biostate AI Secures $12M Series A to Revolutionize RNA Sequencing and Molecular Diagnostics

AIPrecision MedicineOncology
  • Biostate AI has raised $12 million in Series A funding led by Accel to develop affordable RNA sequencing technology and AI-powered diagnostic models.
  • The company's proprietary BIRT and PERD technologies reduce RNAseq costs by nearly an order of magnitude, enabling researchers to run 2-3 times more samples within existing budgets.
  • Founded by former professors David Zhang and Ashwin Gopinath, Biostate AI aims to build "foundation models" for molecular medicine by analyzing billions of RNA expressions to predict disease evolution and drug responses.

Merck and imec Partner to Develop Advanced Microphysiological Systems Platform for Drug Discovery

Drug DiscoveryAI
• Merck and imec have announced a strategic partnership to develop an advanced Microphysiological Systems (MPS) platform that aims to improve drug discovery efficiency and reduce reliance on animal testing.
• The collaboration integrates organoid biology models with semiconductor hardware, incorporating biosensing and microfluidic capabilities to provide real-time insights from individual organs to multi-organ connected systems.
• The jointly developed modular system will feature standardized interfaces compatible with Merck's portfolio of stem cells and patient-derived organoids, enabling more reliable predictions of human organ responses to drug stimuli.

Persist AI Raises $12M Series A, Launches Cloud Lab to Revolutionize Pharmaceutical Formulation Development

AI
  • Persist AI has secured $12 million in Series A funding to expand its AI-driven robotics platform that reduces drug formulation development time from years to months.
  • The company's Cloud Lab platform enables pharmaceutical companies to remotely develop formulations using robotic laboratory facilities, testing 700 formulations in two months compared to the industry standard of 10-15 per month.
  • Persist AI's technology miniaturizes testing processes, requiring just 1 mL of liquid and a few milligrams of material compared to traditional methods that need 1000 mL and several grams.

Persist AI Secures $12M Series A Funding to Revolutionize Pharmaceutical Formulation Development

AI
  • Persist AI has raised $12 million in Series A funding led by Spero Ventures to expand its AI-driven robotic laboratory for pharmaceutical formulation development.
  • The company's newly launched Cloud Lab platform enables pharmaceutical companies to remotely develop and test drug formulations, reducing traditional timelines from a year to just two months.
  • Persist AI's technology supports various drug modalities including peptides, small molecules, and antibodies, with plans to build a GMP manufacturing system for long-acting injectables in collaboration with Nivagen Pharmaceuticals.

Gustave Roussy Launches UMBRELLA Trial: Using Blood-Based Tumor DNA to Revolutionize Cancer Follow-Up Care

OncologyPrecision MedicineAI
  • Gustave Roussy has initiated UMBRELLA, a groundbreaking phase III trial that personalizes post-treatment cancer monitoring based on minimal residual disease (MRD) detected through blood-based circulating tumor DNA analysis.
  • The trial will evaluate two strategies: pre-emptive immunotherapy (tislelizumab) for MRD-positive patients and reduced follow-up schedules for MRD-negative patients with non-metastatic lung, colorectal, pancreatic, and soft tissue sarcomas.
  • UMBRELLA represents the first French multi-cancer trial using MRD status for therapeutic stratification, aiming to enroll over 700 patients across 10-11 centers in a collaborative effort involving Veracyte, IntegraGen, and BeiGene.

tislelizUMaB in canceR Patients With molEcuLar residuaL Disease

NCT06332274RecruitingPhase 3
Gustave Roussy, Cancer Campus, Grand Paris
Posted 4/16/2025

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.